Biologically active molecules that reduce polyglutamine aggregation and toxicity

Human Molecular Genetics

Volumn 15, Issue 13, 2006, Pages 2114-2124

  Desai, Urvee A ^a   Pallos, Judit ^b   Ma, Aye Aye K ^a   Stockwell, Brent R ^d   Thompson, Leslie Michels ^c   Marsh, J Lawrence ^b   Diamond, Marc I ^a  

^a Department of Neurology and Cellular and Molecular Pharmacology ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ATENOLOL; BUTOXAMINE; CASPASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FOSFOSAL; GEFITINIB; HUNTINGTIN; HYDRALAZINE; MOLSIDOMINE; NADOLOL; NEOCOBEFRIN; PICEATANNOL; POLYGLUTAMINE; TODRALAZINE;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DROSOPHILA; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EXON; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ANIMALS; BIOLOGICAL ASSAY; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA MELANOGASTER; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; HUNTINGTON DISEASE; MOLECULAR STRUCTURE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NUCLEAR PROTEINS; PC12 CELLS; PEPTIDES; PROTEIN FOLDING; RATS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRINUCLEOTIDE REPEAT EXPANSION;

MAMMALIA;

EID: 33745239787     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddl135     Document Type: Article

References (54)

1. Harding, A.E., Thomas, P.K., Baraitser, M., Bradbury, P.G., Morgan-Hughes, J.A. and Ponsford, J.R. (1982) X-linked recessive bulbospinal neuropathy: A report of ten cases. J. Neurol. Neurosrurg. Psychiat., 45, 1012-1019.
2. Kennedy, W.R., Alter, M. and Sung, J.H. (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology, 18, 671-680.
3. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. and Fischbeck, K.H. (1991) Androgen receptor gene mutations in X-linked spinobulbar muscular atrophy. Nature, 352, 77-79.
4. Group, H.s.D.C.R. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
5. Cummings, C.J., Reinstein, E., Sun, Y., Antalffy, B., Jiang, Y., Ciechanover, A., Orr, H.T., Beaudet, A.L. and Zoghbi, H.Y. (1999) Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron, 24, 879-892.
6. Zoghbi, H.Y. and Orr, H.T. (1999) Polyglutamine diseases: Protein cleavage and aggregation. Curr. Opin. Neurobiol., 9, 566-570.
7. Cummings, C.J., Sun, Y., Opal, P., Antalffy, B., Mestril, R., Orr, H.T., Dillmann, W.H. and Zoghbi, H.Y. (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet., 10, 1511-1518.
8. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. and Finkbeiner, S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 431, 747-748.
9. Klement, I.A., Skinner, P., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B., Zoghbi, H.Y. and Orr, H.T. (1998) Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell, 95, 41-53.
10. Cowan, K.J., Diamond, M.I. and Welch, W.J. (2003) Polyglutamine protein aggregation and toxicity are linked to the cellular stress response. Hum. Mol. Genet., 12, 1377-1391.
11. Welch, W.J. and Diamond, M.I. (2001) Glucocorticoid modulation of androgen receptor nuclear aggregation and cellular toxicity is associated with distinct forms of soluble expanded polyglutamine protein. Hum. Mol. Genet., 10, 3063-3074.
12. Bence, N.F., Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 292, 1552-1555.
13. Diamond, M.I., Robinson, M.R. and Yamamoto, K.R. (2000) Regulation of expanded polyglutamine protein aggregation and nuclear localization in glucocorticoid receptor. Proc. Natl Acad. Sci., 97, 657-661.
14. Wyttenbach, A., Carmichael, J., Swartz, J., Furlong, R.A., Narain, Y., Rankin, J. and Rubinsztein, D.C. (2000) Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci., 97, 2898-2903.
15. Meriin, A.B., Mabuchi, K., Gabai, V.L., Yaglom, J.A., Kazantsev, A. and Sherman, M.Y. (2001) Intracellular aggregation of polypeptides with expanded polyglutamine domain is stimulated by stress-activated kinase MEKK1. J. Cell Biol., 153, 851-864.
16. Chen, H.K., Fernandez-Funez, P., Acevedo, S.F., Lam, Y.C., Kaytor, M.D., Fernandez, M.H., Aitken, A., Skoulakis, E.M., Orr, H.T., Botas, J. and Zoghbi, H.Y. (2003) Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell, 113, 457-468.
17. Humbert, S., Bryson, E.A., Cordelieres, F.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E. and Saudou, F. (2002) The IGF-1/ Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Cell, 2, 831-837.
18. Sakahira, H., Breuer, P., Hayer-Hartl, M.K. and Hartl, F.U. (2002) Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc. Natl Acad. Sci. USA, 99, 16412-16418.
19. Wang, J., Gines, S., MacDonald, M.E. and Gusella, J.F. (2005) Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci., 6, 1.
20. Georgalis, Y., Starikov, E.B., Hollenbach, B., Lurz, R., Scherzinger, E., Saenger, W., Lehrach, H. and Wanker, E.E. (1998) Huntingtin aggregation monitored by dynamic light scattering. Proc. Natl Acad. Sci. USA, 95, 6118-6121.
21. Piccioni, F., Roman, B.R., Fischbeck, K.H. and Taylor, J.P. (2004) A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum. Mol. Genet., 13, 437-446.
22. Zhang, X., Smith, D.L., Meriin, A.B., Engemann, S., Russel, D.E., Roark, M., Washington, S.L., Maxwell, M.M., Marsh, J.L., Thompson, L.M. et al. (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl Acad. Sci. USA, 102, 892-897.
23. Aiken, C.T., Tobin, A.J. and Schweitzer, E.S. (2004) A cell-based screen for drugs to treat Huntington's disease. Neurobiol. Dis., 16, 546-555.
24. Heiser, V., Engemann, S., Brocker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, R., Schugardt, N., Rautenberg, S. et al. (2002) Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl Acad. Sci., 99, 16400-16406.
25. Kaytor, M.D., Byam, C.E., Tousey, S.K., Stevens, S.D., Zoghbi, H.Y. and Orr, H.T. (2005) A cell-based screen for modulators of ataxin-1 phosphorylation. Hum. Mol. Genet., 14, 1095-1105.
26. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.Z., Greenwald, M. et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 413, 739-743.
27. Smith, D.L., Portier, R., Woodman, B., Hockly, E., Mahal, A., Klunk, W.E., Li, X.J., Wanker, E., Murray, K.D. and Bates, G.P. (2001) Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol. Dis., 8, 1017-1026.
28. Heiser, V., Engemann, S., Boeddrich, A., Nordhoff, E., Lurz, R., Schugardt, N., Lehrach, H. and Wanker, E.E. (2000) Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl Acad. Sci. USA, 97, 6739-6744.
29. Kaemmerer, W.F., Rodrigues, C.M., Steer, C.J. and Low, W.C. (2001) Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype. Neuroscience, 103, 713-724.
30. Wellington, C.L., Singaraja, R., Ellerby, L., Savill, J., Roy, S., Leavitt, B., Cattaneo, E., Hackam, A., Sharp, A., Thornberry, N. et al. (2000) Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells. J. Biol. Chem., 275, 19831-19838.
31. Kim, S.J., Kim, T., Hong, S., Rhim, H., Kim, I.Y. and Kang, S. (2003) Oxidative stimuli affect polyglutamine aggregation and cell death in human mutant ataxin-1-expressing cells. Neurosci. Lett., 348, 21-24.
32. Zeron, M.M., Fernandes, H.B., Krebs, C., Shehadeh, J., Wellington, C.L., Leavitt, B.R., Baimbridge, K.G., Hayden, M.R. and Raymond, L.A. (2004) Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci., 25, 469-479.
33. Ona, V.O., Li, M., Vonsattel, J.P., Andrews, L.J., Khan, S.Q., Chung, W.M., Frey, A.S., Menon, A.S., Li, X.J., Stieg, P.E. et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature, 399, 204-207.
34. Apostol, B.L., Kazantsev, A., Raffioni, S., Illes, K., Pallos, J., Bodai, L., Slepko, N., Bear, J.E., Gertler, F.B., Hersch, S. et al. (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl Acad. Sci., 100, 5950-5955.
35. Pollitt, S.K., Pallos, J., Shao, J., Desai, U.A., Aye Ma, Aye, Thompson, L.M., Marsh, J.L. and Diamond, M.I. (2003) A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron, 40, 685-694.
36. Kim, S., Nollen, E.A., Kitagawa, K., Bindokas, V.P. and Morimoto, R.I. (2002) Polyglutamine protein aggregates are dynamic. Nat. Cell Biol., 4, 826-831.
37. Jorissen, R.N., Walker, F., Pouliot, N., Garrett, T.P., Ward, C.W. and Burgess, A.W. (2003) Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell. Res., 284, 31-53.
38. Yano, S., Kondo, K., Yamaguchi, M., Richmond, G., Hutchison, M., Wakeling, A., Averbuch, S. and Wadsworth, P. (2003) Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res., 23, 3639-3650.
39. Nitz, R.E. and Fiedler, V.B., (1987) Molsidomine: Alternative approaches to treat myocardial ischemia. Pharmacotherapy, 7, 28-37.
40. Greenberg, S., (1999) Modular components of phagocytosis. J. Leukoc. Biol., 66, 712-717.
41. Jiang, K., Zhong, B., Ritchey, C., Gilvary, D.L., Hong-Geller, E., Wei, S. and Djeu, J.Y. (2003) Regulation of Akt-dependent cell survival by Syk and Rac. Blood, 101, 236-244.
42. Narula, S.S., Yuan, R.W., Adams, S.E., Green, O.M., Green, J., Philips, T.B., Zydowsky, L.D., Botfield, M.C., Hatada, M., Laird, E.R. et al. (1995) Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide. Structure, 3, 1061-1073.
43. Yamada, T., Fujieda, S., Yanagi, S., Yamamura, H., Inatome, R., Sunaga, H. and Saito, H. (2001) Protein-tyrosine kinase Syk expressed in human nasal fibroblasts and its effect on RANTES production. J. Immunol., 166, 538-543.
44. Minamiyama, M., Katsuno, M., Adachi, H., Waza, M., Sang, C., Kobayashi, Y., Tanaka, F., Doyu, M., Inukai, A. and Sobue, G. (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet., 13, 1183-1192.
45. Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A. et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA, 100, 2041-2046.
46. Ferrante, R.J., Kubilus, J.K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N.W., Ratan, R.R., Luthi-Carter, R. et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci., 23, 9418-9427.
47. Franceschini, N. and Kirschfeld, K. (1971) Pseudopupil phenomena in the compound eye of Drosophila. Kybernetik, 9, 159-182.
48. Chen, S., Berthelier, V., Yang, W. and Wetzel, R. (2001) Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol., 311, 173-182.
49. Thakur, A.K., Yang, W. and Wetzel, R. (2004) Inhibition of polyglutamine aggregate cytotoxicity by a structure-based elongation inhibitor. FASEB J., 18, 923-925.
50. Yang, W., Dunlap, J.R., Andrews, R.B. and Wetzel, R. (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet., 11, 2905-2917.
51. Apostol, B.L., Kazantsev, A., Raffioni, S., Illes, K., Pallos, J., Bodai, L., Slepko, N., Bear, J.E., Gertler, F.B., Hersch, S. et al. (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl Acad. Sci. USA, 100, 5950-5955.
52. Karpuj, M.V., Becher, M.W., Springer, J.E., Chabas, D., Youssef, S., Pedotti, R., Mitchell, D. and Steinman, L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med., 8, 143-149.
53. Sanchez, I., Mahlke, C. and Yuan, J. (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature, 421, 373-379.
54. Ciardiello, F., De Vita, F., Orditura, M. and Tortora, G. (2004) The role of EGFR inhibitors in non-small cell lung cancer. Curr. Opin. Oncol., 16, 130-135.